Dr. Leath on Ongoing Trials for Endometrial Cancer

Charles A. (Trey) Leath, III, MD
Published Online: Friday, Jun 09, 2017



Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses ongoing trials for patients with endometrial cancer.

Endometrial cancer is the most common gynecologic cancer, explains Leath. However, there is a lot that is unknown regarding the ideal treatment for endometrial cancer.

The PORTEC-3 and GOG 258 compared chemotherapy with various approaches of chemoradiation therapy. Standard chemotherapy has been beneficial; however, the role of radiation needs to be investigated further, states Leath.
 


Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses ongoing trials for patients with endometrial cancer.

Endometrial cancer is the most common gynecologic cancer, explains Leath. However, there is a lot that is unknown regarding the ideal treatment for endometrial cancer.

The PORTEC-3 and GOG 258 compared chemotherapy with various approaches of chemoradiation therapy. Standard chemotherapy has been beneficial; however, the role of radiation needs to be investigated further, states Leath.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Precision Medicine: The Evolving Role of Genomics and Proteomics in Cancer Treatment: Current and Emerging Roles for Molecular Testing Technologies: Real-World Application into PracticeAug 29, 20171.5
Community Practice Connections™: Oncogenic Tumor Board in NSCLC: Targeting Driver Mutations to Maximize Therapeutic OutcomesAug 31, 20171.5
Publication Bottom Border
Border Publication
$emailPop$